41 related articles for article (PubMed ID: 17614009)
1. Elucidating the distinctive regulatory effects and mechanisms of active compounds in Salvia miltiorrhiza Bunge via network pharmacology: Unveiling their roles in the modulation of platelet activation and thrombus formation.
Zhang Y; Xin G; Zhou Q; Yu X; Feng L; Wen A; Zhang K; Wen T; Zhou X; Wu Q; He H; Huang W
Toxicol Appl Pharmacol; 2024 Mar; 484():116871. PubMed ID: 38423217
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect and molecular mechanism of Salvia Miltiorrhiza on rats with acute brain injury after carbon monoxide poisoning based on the strategy of internet pharmacology.
Li ZK; Li CH; Yue AC; Song HP; Liu XH; Zhou XD; Bi MJ; Han W; Li Q
Environ Toxicol; 2022 Mar; 37(3):413-434. PubMed ID: 34761859
[TBL] [Abstract][Full Text] [Related]
3. Flavonoid transport across RBE4 cells: A blood-brain barrier model.
Faria A; Pestana D; Teixeira D; Azevedo J; De Freitas V; Mateus N; Calhau C
Cell Mol Biol Lett; 2010 Jun; 15(2):234-41. PubMed ID: 20140760
[TBL] [Abstract][Full Text] [Related]
4. Potential chemoprotective effects of active ingredients in
Wang Q; Li J; Chu X; Jiang X; Zhang C; Liu F; Zhang X; Li Y; Shen Q; Pang B
Front Cardiovasc Med; 2023; 10():1267525. PubMed ID: 37915739
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Sestrin expression through Tanshinone 2A treatment improves PI3K-dependent inhibition of glioma growth.
Schaf J; Shinhmar S; Zeng Q; Pardo OE; Beesley P; Syed N; Williams RSB
Cell Death Discov; 2023 May; 9(1):172. PubMed ID: 37202382
[TBL] [Abstract][Full Text] [Related]
6. Targeting organic cation transporters at the blood-brain barrier to treat ischemic stroke in rats.
Stanton JA; Williams EI; Betterton RD; Davis TP; Ronaldson PT
Exp Neurol; 2022 Nov; 357():114181. PubMed ID: 35905840
[TBL] [Abstract][Full Text] [Related]
7. Transport Mechanisms at the Blood-Brain Barrier and in Cellular Compartments of the Neurovascular Unit: Focus on CNS Delivery of Small Molecule Drugs.
Ronaldson PT; Davis TP
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890396
[TBL] [Abstract][Full Text] [Related]
8.
Liu J; Shi Y; Peng D; Wang L; Yu N; Wang G; Chen W
Front Cardiovasc Med; 2022; 9():842980. PubMed ID: 35528835
[TBL] [Abstract][Full Text] [Related]
9. Blood-Brain Barrier Transporters: Opportunities for Therapeutic Development in Ischemic Stroke.
Nilles KL; Williams EI; Betterton RD; Davis TP; Ronaldson PT
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163820
[TBL] [Abstract][Full Text] [Related]
10. Intracisternal administration of tanshinone IIA-loaded nanoparticles leads to reduced tissue injury and functional deficits in a porcine model of ischemic stroke.
Waters ES; Kaiser EE; Yang X; Fagan MM; Scheulin KM; Jeon JH; Shin SK; Kinder HA; Kumar A; Platt SR; Duberstein KJ; Park HJ; Xie J; West FD
IBRO Neurosci Rep; 2021 Jun; 10():18-30. PubMed ID: 33842909
[TBL] [Abstract][Full Text] [Related]
11. Advancements in the Blood-Brain Barrier Penetrating Nanoplatforms for Brain Related Disease Diagnostics and Therapeutic Applications.
Thangudu S; Cheng FY; Su CH
Polymers (Basel); 2020 Dec; 12(12):. PubMed ID: 33419339
[TBL] [Abstract][Full Text] [Related]
12. Transporter-mediated natural product-drug interactions for the treatment of cardiovascular diseases.
Zha W
J Food Drug Anal; 2018 Apr; 26(2S):S32-S44. PubMed ID: 29703385
[TBL] [Abstract][Full Text] [Related]
13. Recent insights into the biological activities and drug delivery systems of tanshinones.
Cai Y; Zhang W; Chen Z; Shi Z; He C; Chen M
Int J Nanomedicine; 2016; 11():121-30. PubMed ID: 26792989
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of tanshinone IIA on the brain and its therapeutic time window in rat models of cerebral ischemia-reperfusion.
Tang Q; Han R; Xiao H; Li J; Shen J; Luo Q
Exp Ther Med; 2014 Nov; 8(5):1616-1622. PubMed ID: 25289069
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tissue distribution study of tanshinone IIA after oral administration of Bushen Huoxue Qubi granules to rats with blood stasis syndrome.
Wang Y; Yan J; Li S; Cai X; Wang W; Luo K; Huang D; Gao J
Pharmacogn Mag; 2014 Jul; 10(39):285-91. PubMed ID: 25210316
[TBL] [Abstract][Full Text] [Related]
16. Extracts of Salvia miltiorrhiza Bunge on the cytokines of rat endometriosis models.
Zhou ZH; Weng Q; Zhou JH; Zhou J
Afr J Tradit Complement Altern Med; 2012; 9(3):303-14. PubMed ID: 23983360
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography.
Hooker JM; Kim SW; Alexoff D; Xu Y; Shea C; Reid A; Volkow N; Fowler JS
ACS Chem Neurosci; 2010; 1(1):65-73. PubMed ID: 20657706
[TBL] [Abstract][Full Text] [Related]
18. Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier.
Chen X; Zhou ZW; Xue CC; Li XX; Zhou SF
Xenobiotica; 2007 Jun; 37(6):635-78. PubMed ID: 17614009
[TBL] [Abstract][Full Text] [Related]
19. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier.
Yu XY; Lin SG; Chen X; Zhou ZW; Liang J; Duan W; Chowbay B; Wen JY; Chan E; Cao J; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):365-78. PubMed ID: 17504224
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
